Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -5.00p -10.64% 42.00p 40.00p 44.00p 47.00p 42.00p 47.00p 30,983 16:17:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.6 -0.2 -4.3 - 2.33

Aortech (AOR) Latest News

More Aortech News
Aortech Takeover Rumours

Aortech (AOR) Share Charts

1 Year Aortech Chart

1 Year Aortech Chart

1 Month Aortech Chart

1 Month Aortech Chart

Intraday Aortech Chart

Intraday Aortech Chart

Aortech (AOR) Discussions and Chat

Aortech Forums and Chat

Date Time Title Posts
17/1/201821:37Aortech - Interesting Biomaterials Business. Market Cap All Cash3,586
03/7/201516:20Upwards1
19/1/200716:00Aortech with Charts & News6
07/4/200616:46Wakey Wakey! - Aortec in bid talks......70
05/11/200311:47Aortech is an obvious 2-bagger68

Add a New Thread

Aortech (AOR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:18:1243.008,0003,440.00O
16:17:0341.405,0002,070.00O
15:09:2643.4810,0004,348.00O
14:34:0945.00700315.00O
14:23:2945.00784352.80O
View all Aortech trades in real-time

Aortech (AOR) Top Chat Posts

DateSubject
17/1/2018
08:20
Aortech Daily Update: Aortech International is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker AOR. The last closing price for Aortech was 47p.
Aortech International has a 4 week average price of 37.50p and a 12 week average price of 18p.
The 1 year high share price is 69.50p while the 1 year low share price is currently 9.25p.
There are currently 5,557,695 shares in issue and the average daily traded volume is 52,582 shares. The market capitalisation of Aortech International is £2,334,231.90.
09/1/2018
12:59
mikeh30: The results for the year to 31 March 2017 the share price was implying that AorTech was likely to fail.The recent trading results should indicate to shareholders that the business is on a more stable footing and the risk of failure diminished. The cash position improved during the six months to 30 September 2017 and at the end of November 2017 had further increased to $328,000. We anticipate that the net cash position should improve further.A detailed strategic plan to allow AorTech to commercialise its platform technology is currently being considered and we will report to shareholders when the process is concluded
15/12/2017
10:59
stephen2010: As I posted yesterday evening. Check out ALBA. Huge multibag potential. ALBA currently trading at 0.39p target price 6p making a nice 15 bagger. Please read the following: MARKET CAP PUZZLE ❖ Alba (market cap £8.4m) is in a resources neighbourhood populated with listed companies with much enhanced market capitalisations, such as UKOG.L (£134m) and JAY.L (£172m). With either shared project interests or adjacent tenements to these companies, Alba should trade at a much higher valuation than its current token value. Like Bluejay, Alba owns 100% of its ilmenite project. Direct comparisons with UKOG are also instructive. While both companies own other projects, UKOG’s 49.9% of Horse Hill Developments Limited (HHDL), when compared to Alba’s 18.1% means that Alba has approximately one third of the value of Horse Hill compared to UKOG but only about 7% of the market capitalisation. Once the market recognises these disparities, the room for growth in Alba’s share price is undeniable. VALUATION RATIONALE - Our valuation in this First Equity Limited initiation note uses a risked valuation approach for Alba’s two main projects, at Horse Hill and TBS. The Horse Hill licences are valued using independent published technical data from Schlumberger, Xodus and Nutech on the oil potential of the licences, along with our own assumptions on recovery rates, oil discovery value, resource and development risks factors. From this a risked value of $127m net to Alba on a ‘Base Case’ basis is derived for Horse Hill. Given the similar geology and economic potential of both TBS and Dundas, we have adopted a risked closeology valuation approach, by computing an NPV for Dundas of $223m and then applying a three-tiered risked probability calculation to arrive at a value of $54.7m for TBS. Once Alba announce its JORC resource and exploration target at TBS and Bluejay its Feasibility Study results, this number is likely to be revised upwards very rapidly, possibly up to $200m, representing up to 7p per share in additional shareholder value. We compute a valuation of $185m (£139m) for Alba, equating to 6.0p per share, of which 4.1p is attributed to the stake in Horse Hill, 1.8p for TBS. Given this analysis and wealth of valuation catalysts anticipated across the project portfolio in the coming months, we recommend the shares as a ‘BUY, with a Target Price of 6.0p, representing a potential 15 times plus uplift from the current share price.
13/12/2017
10:37
landy90: Back to basics: Business is cash generative. On a 4X multiple current licenses worth at least 33p a share. Cash at end Nov worth another 5p. Value of settlement...? Minimum share price should be 40p plus growth potential.
13/12/2017
10:01
only winners please: Look at this companies valuation of £2M , then deduct the cash, cash due, and then add on some on for the settlement. In effect your getting the company for about one million pounds. That’s very very cheap. The recurring revenues are worth about 40 times on a pe basis. If Turnover can grow fast then your looking at a 40 times rise in the share price. Take absolutely no notice of the share price it’s the market cap that counts. Just 5.5 million shares in issue.
13/12/2017
09:47
donalc: We are disappointed because we have doubled in value over last month? this will be and will always be a very volatile share with huge potential. If it delivers we will all retire gracefully , if it does not life goes on. Population demography changes in the next 10 years mean the market this is playing into is rising at a phenomenal and scary rate. I am a GP struggling with current demography , interventions in this population will rise. Activity in most areas is around 5% per year. If the board make the right relationships, and remain authentic this should do well. Close your eyes for the next few months. The ride will be very bumpy- but that is healthy compared to a flat line share price.
12/12/2017
11:41
orange1: But then there was a hell of a lot of selling yesterday, as Richard Griffith liquidated his position (near 10%): https://uk.advfn.com/stock-market/london/aortech-AOR/share-news/AorTech-International-PLC-Holdings-in-Company/76275402
12/12/2017
09:38
the stigologist: I've been following AOR for months and purchased initial position at 20p I've bought more this morning at mid 50s Unfortunately a lot of AIM punters only look at the share price. So they think 50p is 'expensive'. Obviously those of us who are more intelligent know it's the Market Cap that counts. Just some valuation pointers to compare with our £2.5-3.0m mkt cap tiddler. Biomerics our main licensee is spending $38m just to buy a new HQ building There have been several recent fundings and takeovers in this space which gives an indication of the real value to Corporates of this sort of technology e.g. Xeltis got $52m in Series C funding (implies $ X hundred million market cap ) htTps://www.fiercebiotech.com/medtech/xeltis-lands-52-million-for-restorative-heart-valve-tech Harpoon Medical acquired for $100m by Edward Lifesciences htTp://www.baltimoresun.com/business/bs-md-ci-harpoon-medical-acquired-20171206-story.html I think there is a reason AOR talked about the value of their licences versus their Market Cap as I'd imagine they have been approached by many interested parties. Huge value in this long term. £25-30m (i.e. 10x current cap) should be seen as the starting point
11/12/2017
12:31
mikeh30: Well the fact they say the share price was based on Aortech failing (which it is not) is a good place to start
11/12/2017
12:17
mikeh30: The long-running litigation dispute created a number of uncertainties for AorTech and its shareholders and at the time of announcing results for the year to 31 March 2017 the share price was implying that AorTech was likely to fail.Not going to fail now. £2.5m cap. Used to trade between 500-1000p when it wasn't priced to fail
11/12/2017
11:14
mikeh30: The long-running litigation dispute created a number of uncertainties for AorTech and its shareholders and at the time of announcing results for the year to 31 March 2017 the share price was implying that AorTech was likely to fail.
Aortech share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180117 22:04:27